For Healthcare Professionals

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)


About the study

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate cancer (mCRPC).

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Male ≥18 years of age at the time of signing informed consent
  2. Histologically or cytologically confirmed adenocarcinoma of the prostate
  3. Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible
  4. Adequate organ function


Exclusion Criteria:

  1. Prior solid organ transplant
  2. Prior treatment with PSMA-targeted CAR-T cell therapy
  3. Clinically significant cardiovascular disease
  4. Active clinically significant infection (bacterial, viral, fungal, mycobacteria or other)
  5. Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Prostate Cancer,Metastatic Castration-resistant Prostate Cancer,Castration Resistant Prostatic Cancer

Age (in years)

18 - 100


Phase 1

Participants needed


Est. Completion Date

Mar 31, 2025

Treatment type



Janux Therapeutics identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.